Search Patents
  • Medicinal acidic cannabinoids
    Patent number: 7807711
    Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: October 5, 2010
    Assignee: Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
    Inventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
  • USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT
    Publication number: 20110038958
    Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
    Type: Application
    Filed: December 17, 2008
    Publication date: February 17, 2011
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
  • PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20140221469
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.
    Type: Application
    Filed: September 10, 2012
    Publication date: August 7, 2014
    Applicants: Otsuka Pharmaceutical Co., Ltd., GW Pharma Limited
    Inventors: Ruth Alexandra Ross, Daniela Parolaro
  • ANTI-MICROBIAL COMPOSITION COMPRISING CANNABINOIDS
    Publication number: 20160374958
    Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
    Type: Application
    Filed: June 21, 2016
    Publication date: December 29, 2016
    Inventors: George E. Anastassov, Lekhram Changoer, Phillipus Anne Van Damme
  • CANNABIGEROL QUINONE ACID AND SALTS THEREOF
    Publication number: 20220041538
    Abstract: A compound of formula I or a pharmaceutical salt thereof of formula II, as well as a process to obtain said compound and a process to obtain said salt. Additionally, disclosed is the use of said compound of formula I or said pharmaceutical salt thereof of formula II as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, for use in the treatment or prevention of a disease responsive to PPAR? agonists. Also disclosed is a pharmaceutical composition comprising said compound or said salt, as well as a method of treating or preventing a disease with said compound of formula I or said salt thereof of formula II, or with a composition comprising said compound or said salt.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 10, 2022
    Applicant: EMERALD HEALTH PHARMACEUTICALS INC
    Inventors: Eduardo MUÑOZ BLANCO, Giovanni APPENDINO
  • USE OF CANNABINOID COMPOUNDS TO TREAT OR PREVENT FUNGAL GROWTH OF C. ALBICANS
    Publication number: 20230082130
    Abstract: Methods of treating or preventing the growth of Candida albicans (“C. albicans”) using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabidivarin (“CBDV”), cannabidiorcol (“CBD-C1”), cannabidol-C2 (“CBD-C2”), cannabidol-C4 (“CBD-C4”), cannabigerivarin (“CBGV”), cannabidol (“CBD”), and cannabigerol butyl (“CBG-C4”). The methods can be used to treat or prevent oral thrush, athlete's foot, vaginal (yeast) infections, systemic infections, and other infections. Compositions and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: September 7, 2022
    Publication date: March 16, 2023
    Inventors: Cynthia W. Byrant, Alison Watta
  • Oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues
    Patent number: 10918686
    Abstract: Disclosed is an oleo gel composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin and Cannabigerol in combination with extract of Olive europaea Fruit Oil, Mentha arvensis leaf oil, and Silica colloidal anhydrous ensuring the delivery of cannabinoids to the deep tissues in order to reduce pain and inflammation of skeletal muscles and joints caused by trauma or/and induced by arthritis/osteoarthritis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 16, 2021
    Assignee: UAB Satimed
    Inventor: Juozas Siurkus
  • ANTI-MICROBIAL COMPOSITION COMPRISING CANNABINOIDS
    Publication number: 20190209487
    Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 11, 2019
    Inventors: George E. Anastassov, Lekhram Changoer, Philippus Anne Van Damme
  • ANTI-MICROBIAL COMPOSITIONS COMPRISING CANNABINOIDS
    Publication number: 20200016095
    Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
    Type: Application
    Filed: August 20, 2019
    Publication date: January 16, 2020
    Inventors: George E. Anastassov, Lekhram Changoer, Phillippus Anne Van Damme
  • THE TOPICAL COMPOSITION WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND CALENDULA OFFICINALIS FOR REDUCTION OF SKIN LESIONS
    Publication number: 20190111093
    Abstract: Disclosed is a topical composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores and exert soothing effect.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 18, 2019
    Inventors: Juozas SIURKUS, Rimantas PECIURA
  • Cannabinoid Composition and Method For Treating Pain
    Publication number: 20170027978
    Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis Indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC”), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa).
    Type: Application
    Filed: September 16, 2015
    Publication date: February 2, 2017
    Applicant: India Globalization Capital, Inc.
    Inventors: Ramachandra MUKUNDA, Ranga Chelva KRISHNA
  • ENCAPSULATED CANNABINOID FORMULATIONS FOR ORAL DELIVERY
    Publication number: 20200338150
    Abstract: Preparation of cannabinoid formulations containing: ?9-tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), ?9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. These preparations demonstrates the viability of sublingual, buccal, or oral delivery using an aqueous-based encapsulation method, including as a beverage or drink.
    Type: Application
    Filed: July 8, 2020
    Publication date: October 29, 2020
    Applicant: Nutrae, LLC
    Inventors: Jacqueline L. Salm, Christopher G. Witowski
  • Smoking Substitute Consumable
    Publication number: 20210219597
    Abstract: An aerosol-forming article (e.g. a heat-not-burn consumable) comprising an aerosol-forming substrate formed of a plurality of longitudinally-aligned, elongate shreds of plant material, wherein the plant material comprises at least one cannabinoid compound selected from cannabidiol (CBD) and its derivatives/homologues, cannabigerol (CBG) and its derivatives/homologues, cannabinol (CBN) and its derivatives/homologues, tetrahydrocannabinol (THC) and its derivatives/homologues, cannabicyclol (CBL) and its derivatives/homologues, cannabichromene (CBC) and its derivatives/homologues, cannabielsoin (CBE) and its derivatives/homologues, cannabicitran (CBT) and its derivatives/homologues.
    Type: Application
    Filed: April 2, 2021
    Publication date: July 22, 2021
    Inventors: Kate Ferrie, Edward Ross Shenton, John Williams, Jill Jones, Christopher Lord
  • Use of cannabinoids in combination with an anti-psychotic medicament
    Patent number: 9017737
    Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 28, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
  • PARENTERAL FORMULATIONS
    Publication number: 20190314296
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: June 29, 2017
    Publication date: October 17, 2019
    Inventors: Stephen Wright, Jitinder WILKHU
  • ENCAPSULATED CANNABINOID FORMULATIONS FOR TRANSDERMAL DELIVERY
    Publication number: 20190216870
    Abstract: Preparation of cannabinoid formulations containing: ?9-tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), ?9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: Nutrae, LLC
    Inventors: Christopher G. Witowski, Jacqueline L. Salm
  • Topical formulations of resorcinols and cannibinoids and methods of use
    Publication number: 20030232101
    Abstract: In one aspect, the invention provides a method for preventing the transmission of HIV from one individual to another. In accordance with the method, a pharmacologically-acceptable composition including at least one resorcinol derivative compound and/or cannabinoid (e.g., cannabinol derivatives, &Dgr;8-THC derivatives, cannabichromene derivatives, cannabidiol derivatives, cannabigerol derivatives) (including combinations thereof) is administered topically to a first individual harboring HIV, or to a second individual at risk of infection with HIV, proximate in time with contact between the first individual and the second individual. The invention also provides topical formulations of at least one resorcinol and/or cannabinoid and water insoluble polymers as hydrogels.
    Type: Application
    Filed: March 18, 2003
    Publication date: December 18, 2003
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS
    Publication number: 20220218654
    Abstract: Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of ?-humulene and/or ?-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an Enterococcus faecium or an Enterococcus faecalis. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 14, 2022
    Inventors: Charles J. Thompson, Mark C. Pryjma, Dana M. Lambert, Manisha Dosanjh
  • Antibiotic cannabinoid-terpene formulations
    Patent number: 11744819
    Abstract: Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of a-humulene and/or ?-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an Enterococcus faecium or an Enterococcus faecalis. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: September 5, 2023
    Assignee: The University of British Columbia
    Inventors: Charles J. Thompson, Mark C. Pryjma, Dana M. Lambert, Manisha Dosanjh
  • Encapsulated cannabinoid formulations for oral delivery
    Patent number: 10709747
    Abstract: Preparation of cannabinoid formulations containing: ?9-tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), ?9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as Cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. These preparations demonstrates the viability of sublingual, buccal, or oral delivery using an aqueous-based encapsulation method, including as a beverage or drink.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: July 14, 2020
    Assignee: NUTRAE, LLC
    Inventors: Jacqueline L. Salm, Christopher G. Witowski
Narrow Results

Filter by US Classification